Literature DB >> 14503801

Involvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomas.

M Cecilia Daroqui1, Lydia I Puricelli, Alejandro J Urtreger, Patricia V Elizalde, Guillermo M Lanuza, Elisa Bal de Kier Joffé.   

Abstract

We studied the expression of TGF-beta/T(beta)R system and its biological role in tumor development, in M3 and MM3 murine mammary adenocarcinomas with different metastasizing capability and in LM3 and LMM3 derived cell lines. All the studied cells secreted TGF-beta(s) and expressed T(beta)Rs. While the proliferation of the poorly metastatic M3 cells was significantly inhibited by 4 ng/ml TGF-beta(s), the highly metastatic MM3 cells were only slightly inhibited in response to the highest dose used. LM3 and LMM3 cells, highly invasive and metastatic, were totally refractory to TGF-beta antiproliferative effect. The role of TGF-beta in modulating key proteolytic cascades in tumor progression was also studied. TGF-beta(s) enhanced metalloproteinases production in all the studied cells while induced a stimulatory net effect on plasmin system activity only in the more metastatic cells. Our results in this murine mammary tumor lineage support the concept that dissociation of TGF-beta regulated growth control versus proteolytic enzyme pathways promotes tumor dissemination.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14503801     DOI: 10.1023/a:1024910332621

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  2 in total

1.  Transcriptional attenuation in colon carcinoma cells in response to butyrate.

Authors:  Maria C Daroqui; Leonard H Augenlicht
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-14

2.  TGF-β autocrine pathway and MAPK signaling promote cell invasiveness and in vivo mammary adenocarcinoma tumor progression.

Authors:  María Cecilia Daroqui; Paula Vazquez; Elisa Bal de Kier Joffé; Andrei V Bakin; Lydia I Puricelli
Journal:  Oncol Rep       Date:  2012-05-14       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.